Clinical Trial Update: Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection

View source ↗

Summary

A clinical trial is evaluating whether circulating tumor DNA can detect minimal residual disease after surgical resection of non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: University Health Network, Toronto | Conditions: Non Small Cell Lung Cancer | Status: RECRUITING